PMID- 30506494
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1869-6953 (Print)
IS  - 1869-6961 (Electronic)
IS  - 1869-6961 (Linking)
VI  - 10
IP  - 1
DP  - 2019 Feb
TI  - Differential Effects of Thiazolidinediones and Dipeptidyl Peptidase-4 Inhibitors 
      on Insulin Resistance and beta-Cell Function in Type 2 Diabetes Mellitus: A 
      Propensity Score-Matched Analysis.
PG  - 149-158
LID - 10.1007/s13300-018-0541-y [doi]
AB  - INTRODUCTION: Comparisons of the glycemic durability between thiazolidinediones 
      (TZDs) and dipeptidyl peptidase-4 (DPP-4) inhibitors remain insufficient. This 
      study aimed to find clues for the differences in glycemic durability between TZDs 
      and DPP-4 inhibitors by comparing the insulin resistance and beta-cell function 
      among patients using these agents. METHODS: A total of 241 patients with type 2 
      diabetes mellitus (T2DM) treated with either pioglitazone (a TZD) or DPP-4 
      inhibitors as combination therapy with metformin for at least 1 year were 
      analyzed. A propensity score based on the patients' baseline characteristics and 
      glycated hemoglobin (HbA1c) was used to match them. Indices for insulin 
      resistance and secretory function of beta-cells, namely the homeostasis model 
      assessment of insulin resistance (HOMA-IR) or beta-cells (HOMA-beta), were calculated 
      and compared. Multiple regression analysis was performed to find the independent 
      variables correlated with beta-cell function or insulin resistance. RESULTS: 
      Evaluation of the data from 168 matched patients with T2DM showed that TZD users 
      had significantly better insulin sensitivity compared with DPP-4 inhibitor users 
      (HOMA-IR 2.3 +/- 1.9 vs. 3.5 +/- 3.2, p = 0.003). Conversely, DPP-4 inhibitor users 
      secreted more insulin than TZD users (HOMA-beta 45.7 +/- 31.6 vs. 61.4 +/- 49.5, 
      p = 0.016). Multiple linear regression analysis showed that these agents were 
      independently associated with both insulin resistance and beta-cell function. 
      CONCLUSION: TZD users showed significantly better insulin sensitivity, whereas 
      DPP-4 inhibitor users secreted more insulin from beta-cells under similar glycemic 
      control.
FAU - Bae, Jaehyun
AU  - Bae J
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei 
      University College of Medicine, Seoul, Republic of Korea.
FAU - Kim, Gyuri
AU  - Kim G
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei 
      University College of Medicine, Seoul, Republic of Korea.
AD  - Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical 
      Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
FAU - Lee, Yong-Ho
AU  - Lee YH
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei 
      University College of Medicine, Seoul, Republic of Korea.
FAU - Lee, Byung-Wan
AU  - Lee BW
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei 
      University College of Medicine, Seoul, Republic of Korea.
FAU - Kang, Eun Seok
AU  - Kang ES
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei 
      University College of Medicine, Seoul, Republic of Korea.
FAU - Cha, Bong-Soo
AU  - Cha BS
AUID- ORCID: 0000-0003-0542-2854
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei 
      University College of Medicine, Seoul, Republic of Korea. BSCHA@yuhs.ac.
LA  - eng
PT  - Journal Article
DEP - 20181201
PL  - United States
TA  - Diabetes Ther
JT  - Diabetes therapy : research, treatment and education of diabetes and related 
      disorders
JID - 101539025
PMC - PMC6349276
OTO - NOTNLM
OT  - Antidiabetic agents
OT  - Dipeptidyl-peptidase 4 inhibitors
OT  - Insulin resistance
OT  - Thiazolidinedione
OT  - beta-Cell function
EDAT- 2018/12/07 06:00
MHDA- 2018/12/07 06:01
PMCR- 2018/12/01
CRDT- 2018/12/04 06:00
PHST- 2018/09/07 00:00 [received]
PHST- 2018/12/07 06:00 [pubmed]
PHST- 2018/12/07 06:01 [medline]
PHST- 2018/12/04 06:00 [entrez]
PHST- 2018/12/01 00:00 [pmc-release]
AID - 10.1007/s13300-018-0541-y [pii]
AID - 541 [pii]
AID - 10.1007/s13300-018-0541-y [doi]
PST - ppublish
SO  - Diabetes Ther. 2019 Feb;10(1):149-158. doi: 10.1007/s13300-018-0541-y. Epub 2018 
      Dec 1.